Skip to content
-
Subscribe to our newsletter & never miss our best posts. Subscribe Now!
Today's News. Tomorrow's Perspective. Today's News. Tomorrow's Perspective.

Deliver fast, factual, and easy-to-understand news covering global events, technology, business, science, AI, health, entertainment, and lifestyle.

Today's News. Tomorrow's Perspective. Today's News. Tomorrow's Perspective.

Deliver fast, factual, and easy-to-understand news covering global events, technology, business, science, AI, health, entertainment, and lifestyle.

  • Home
  • Breaking News
  • Business
  • Sports
  • Health
  • Politics
  • Technology & AI
  • World
  • Home
  • Breaking News
  • Business
  • Sports
  • Health
  • Politics
  • Technology & AI
  • World
Close

Search

Subscribe
SELLAS Life Sciences stock soars 240% following positive cancer trial
Business

SELLAS Life Sciences stock soars 240% following positive cancer trial

jack colman
By jack colman
November 17, 2026 2 Min Read
Comments Off on SELLAS Life Sciences stock soars 240% following positive cancer trial

Investing.com — Shares of SELLAS Life Sciences Group (NASDAQ: SLS) jumped 240% after the company announced positive top-line results from its pivotal Phase 3 REGAL trial of galinpepimut-S (GPS), an immunotherapeutic vaccine for acute myeloid leukemia.

Our AI stock portfolio beats the S&P 500 by 118%. Find out what stocks we’re buying and what opportunities we’re watching next. Exclusive to Yahoo! Financial readers: 55% off for Black Friday, plus an extra 15% at checkout. Subscribe today! »

The REGAL trial met its primary endpoint of overall survival, with GPS demonstrating a 41% reduction in the risk of death compared to the best available treatment. The trial showed a median overall survival of 24.0 months for GPS-treated patients compared to 14.7 months for the control group, with a hazard ratio of 0.59 and a two-sided p-value of 0.035.

The trial evaluated GPS as maintenance monotherapy in patients with acute myeloid leukemia who achieved complete remission at least a second time after second-line or higher salvage therapy and who were ineligible or unable to undergo allogeneic stem cell transplantation.

Stop chasing stocks once they have already rebounded. Find your next investment opportunity with AI stock selection, earnings insights, and market development news. Yahoo! Financial readers get an extra 15% off on top of the 55% off Black Friday price. Join us today! »

GPS was generally well tolerated, with a safety profile consistent with previous clinical experience and no new safety signals were identified. Treatment-related adverse events were mostly mild to moderate, most commonly consisting of local reactions at the injection site.

Analysis of primary endpoint data was performed following the prespecified occurrence of 80 events, in accordance with the trial’s prespecified statistical analysis plan. SELLAS plans to meet with the U.S. Food and Drug Administration to discuss an expedited filing strategy and advance preparations for submitting a Biologics License Application for GPS in the first half of 2027.

A full statistical evaluation of all secondary endpoints and additional prespecified analyzes are underway and will be presented at an upcoming medical conference and submitted for publication in a peer-reviewed journal.

Original article

SELLAS Life Sciences stock soars 240% following positive cancer trial

European stocks fall on new US chip restrictions; Nvidia expected

Bernstein reduces PepsiCo to underperformance in the face of North American pressure

Gn bussni

Views: 3
jack colman
Author

jack colman

**Jack** is a staff journalist and digital content writer at **DailyVoxa**, specializing in breaking news, technology, artificial intelligence, business, and global affairs. He is passionate about transforming complex topics into clear, accurate, and engaging stories that help readers stay informed.With a strong focus on fact-based reporting and thorough research, Jack monitors developing events, analyzes reliable sources, and delivers timely news with clarity and context. His work emphasizes accuracy, transparency, and editorial integrity while avoiding sensationalism.At DailyVoxa, every article written by Jack follows the publication's Editorial Policy, Fact-Checking Policy, and Ethics Policy. He is committed to providing trustworthy journalism that empowers readers with reliable information and meaningful insights into the stories shaping the world.

Follow Me
Other Articles
Georgia, Kansas and Texas consider Medicaid expansion after midterm battles
Previous

Georgia, Kansas and Texas consider Medicaid expansion after midterm battles

MP to challenge Shakespeare's 'ill-considered' decision - BBC News Africa
Next

MP to challenge Shakespeare’s ‘ill-considered’ decision – BBC News Africa

Deliver fast, factual, and easy-to-understand news covering global events, technology, business, science, AI, health, entertainment, and lifestyle.
  • About Us
  • Accessibility Statement
  • Advertise With Us
  • AI Usage & Transparency Policy
  • Contact us
  • Cookie Policy
  • Corrections Policy
  • Meet Our Team
  • Privacy Policy
    • Disclaimer
    • DMCA & Copyright Policy
    • Editorial Policy
    • Ethics Policy
    • Fact-Checking Policy
  • Terms and Conditions
Copyright 2026 — Today's News. Tomorrow's Perspective.. All rights reserved.